Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials

Clin Infect Dis. 2021 Sep 15;73(6):e1380-e1383. doi: 10.1093/cid/ciab386.

Abstract

This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2-882). Overall survival was 82% at day 42 and 70% at day 84.

Keywords: Isavuconazole; fungal sinusitis; invasive aspergillosis; invasive fungal sinusitis; mucormycosis.

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / therapeutic use
  • Aspergillosis* / drug therapy
  • Humans
  • Invasive Fungal Infections* / drug therapy
  • Mucormycosis* / drug therapy
  • Nitriles / therapeutic use
  • Pyridines
  • Sinusitis* / drug therapy
  • Triazoles

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole